First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mjhic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R; Swiss Group for Clinical Cancer Research (SAKK), (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of oncology, 23(2), pp. 531-6. Oxford: Oxford University Press 10.1093/annonc/mdr126

[img]
Preview
Text
mdr126.pdf - Published Version
Available under License Publisher holds Copyright.

Download (127kB) | Preview

Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to temozolomide to improve efficacy in stage IV melanoma.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Ochsenbein, Adrian

ISSN:

0923-7534

Publisher:

Oxford University Press

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:20

Last Modified:

23 Oct 2019 07:55

Publisher DOI:

10.1093/annonc/mdr126

PubMed ID:

21527587

Web of Science ID:

000299744400037

BORIS DOI:

10.7892/boris.6459

URI:

https://boris.unibe.ch/id/eprint/6459 (FactScience: 211425)

Actions (login required)

Edit item Edit item
Provide Feedback